Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming ...

The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

Shares of digital healthcare provider, Hims & Hers Heath (NYSE:HIMS) dropped post market, after it reported Q2 revenue below expectations, hurt by challenges in the compounding obesity drugs market.

Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Unless you’ve been living on another planet over the past few years, you have heard of and probably know several people that ...

Pediatricians in Utah can prescribe weight loss drugs for adolescents over 12 years of age, according to the American Academy ...